ArticleDermatology and therapy2026
Holistic Value Assessment of Tirbanibulin for Actinic Keratosis: European Multi-Criteria Decision Analysis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionActinic keratosis (AK) is a prevalent, chronic skin condition and a precursor to cutaneous squamous cell carcinoma. Effective, patient-friendly therapies that target both visible and subclinical lesions are essential. Tirbanibulin, a topical microtubule inhibitor, is the latest treatment approved in the USA and European Union (EU) for treating non-hyperkeratotic, non-hypertrophic AK on the face and scalp. This study aimed to assess the overall value of tirbanibulin for treating AK on the face or scalp across Germany, Italy, and Spain and to identify key value drivers using a multi-stakeholder perspective.
methodsThis study used a multi-criteria decision analysis (MCDA) to assess the holistic value of tirbanibulin compared with 5-fluorouracil 4% (5FU-4%) across Germany, Italy, and Spain. The validated EVIDEM MCDA framework (tenth edition) included eleven criteria related to disease burden, treatment benefits, evidence quality, and comparative outcomes. A total of 18 participants-dermatologists, payers, and patients-evaluated the treatments in a two-phase process. Phase 1 involved weighing the criteria, and phase 2 involved scoring clinical, economic, and patient-reported evidence for both treatments. Results from both phases were used to calculate an estimated value. The approach supports transparent, stakeholder-informed decision-making for AK treatment.
resultsAll criteria were rated as relevant, with the greatest importance assigned to "comparative safety/tolerability," "quality of evidence," and "comparative efficacy." Tirbanibulin received positive scores across all criteria, particularly for "expert consensus/guidelines," "quality of evidence," and "size of the affected population." The final estimated value of tirbanibulin was 0.622 on a -1 to +1 scale, indicating high perceived value. Value estimations were consistent across stakeholder types, with slight country-level variations.
conclusionsOverall, participants recognized tirbanibulin as a valuable treatment for AK, on the basis of robust evidence, favorable safety/tolerability and patient-reported outcomes (PRO) profiles, and alignment with clinical guidelines, with similar efficacy compared with 5FU-4%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.